Maimonides Biomedical Research Institute of Córdoba (IMIBIC), Córdoba, Spain.
Faculty of Medicine, University of Córdoba, IMIBIC, Córdoba, Spain.
Ital J Pediatr. 2023 Mar 9;49(1):29. doi: 10.1186/s13052-023-01434-7.
Non-alcoholic fatty liver disease is associated with obesity. A subclinical inflammation state, endothelial dysfunction, and parameters related to metabolic syndrome (MetS), have been documented in children with obesity. We aimed to determine the changes that occur in liver enzymes levels in response to the standard treatment of childhood obesity, also assessing any associations with liver enzyme levels, leptin, and markers of insulin resistance (IR), inflammation, and parameters related to MetS in prepubertal children.
We carried out a longitudinal study in prepubertal children (aged 6-9 years) of both sexes with obesity; a total of 63 participants were recruited. Liver enzymes, C-reactive protein (CRP), interleukin-6, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), soluble intercellular adhesion molecule-1 (sICAM-1), leptin, homeostasis model assessment for IR (HOMA-IR), and parameters related to MetS were measured.
After standard treatment for 9 months, children who lowered their standardised body mass index (SDS-BMI) had significantly lower systolic blood pressure (p = 0.0242), diastolic blood pressure (p = 0.0002), HOMA-IR (p = 0.0061), and levels of alanine aminotransferase (ALT) (p = 0.0048), CRP (p = 0.0001), sICAM-1 (p = 0.0460), and IL-6 (p = 0.0438). There was a significant association between the changes that occur with treatment, in the ALT levels, and changes in leptin (p = 0.0096), inflammation biomarkers [CRP (p = 0.0061), IL-6 (p = 0.0337), NLR (p = 0.0458), PLR (p = 0.0134)], and HOMA-IR (p = 0.0322).
Our results showed that a decrease in ALT levels after the standard treatment for 9 months was associated with favourable changes in IR markers (HOMA-IR) and inflammation (IL-6, CRP, NLR, and PLR).
非酒精性脂肪性肝病与肥胖有关。在肥胖儿童中,已记录到亚临床炎症状态、内皮功能障碍以及与代谢综合征(MetS)相关的参数。我们旨在确定儿童肥胖标准治疗后肝酶水平的变化,并评估其与肝酶水平、瘦素和胰岛素抵抗(IR)标志物、炎症以及与青春期前儿童 MetS 相关的参数之间的任何关联。
我们对 6-9 岁的肥胖男女青春期前儿童进行了一项纵向研究;共招募了 63 名参与者。测量了肝酶、C 反应蛋白(CRP)、白细胞介素 6、中性粒细胞与淋巴细胞比值(NLR)、血小板与淋巴细胞比值(PLR)、可溶性细胞间黏附分子 1(sICAM-1)、瘦素、胰岛素抵抗的稳态模型评估(HOMA-IR)和与 MetS 相关的参数。
经过 9 个月的标准治疗后,标准体重指数(SDS-BMI)降低的儿童收缩压(p=0.0242)、舒张压(p=0.0002)、HOMA-IR(p=0.0061)和丙氨酸氨基转移酶(ALT)水平(p=0.0048)、CRP(p=0.0001)、sICAM-1(p=0.0460)和 IL-6(p=0.0438)均显著降低。ALT 水平治疗后变化与瘦素(p=0.0096)、炎症生物标志物[CRP(p=0.0061)、IL-6(p=0.0337)、NLR(p=0.0458)、PLR(p=0.0134)]和 HOMA-IR(p=0.0322)的变化之间存在显著关联。
我们的研究结果表明,标准治疗 9 个月后 ALT 水平的降低与 IR 标志物(HOMA-IR)和炎症(IL-6、CRP、NLR 和 PLR)的有利变化有关。